Advertisement
Research Article

Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia

  • Zheng Hu equal contributor,

    equal contributor Contributed equally to this work with: Zheng Hu, Xiao-Fen Pan, Fu-Qun Wu, Li-Yuan Ma

    Affiliation: Laboratory of Molecular Target-Based Therapy for Cancer, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China

    X
  • Xiao-Fen Pan equal contributor,

    equal contributor Contributed equally to this work with: Zheng Hu, Xiao-Fen Pan, Fu-Qun Wu, Li-Yuan Ma

    Affiliation: Laboratory of Molecular Target-Based Therapy for Cancer, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China

    X
  • Fu-Qun Wu equal contributor,

    equal contributor Contributed equally to this work with: Zheng Hu, Xiao-Fen Pan, Fu-Qun Wu, Li-Yuan Ma

    Affiliation: Laboratory of Molecular Target-Based Therapy for Cancer, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China

    X
  • Li-Yuan Ma equal contributor,

    equal contributor Contributed equally to this work with: Zheng Hu, Xiao-Fen Pan, Fu-Qun Wu, Li-Yuan Ma

    Affiliation: State Key Laboratory of Medical Genomics and Shanghai Institute of Hematology, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

    X
  • Da-Peng Liu,

    Affiliation: Laboratory of Molecular Target-Based Therapy for Cancer, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China

    X
  • Ying Liu,

    Affiliations: Laboratory of Molecular Target-Based Therapy for Cancer, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China, University of Science and Technology of China, Hefei, China

    X
  • Ting-Ting Feng,

    Affiliations: Laboratory of Molecular Target-Based Therapy for Cancer, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China, University of Science and Technology of China, Hefei, China

    X
  • Fan-Yi Meng,

    Affiliation: Department of Hematology, Nanfang Hospital Affiliated to Nanfang Medical University, Guangzhou, China

    X
  • Xiao-Li Liu,

    Affiliation: Department of Hematology, Nanfang Hospital Affiliated to Nanfang Medical University, Guangzhou, China

    X
  • Qian-Li Jiang,

    Affiliation: Department of Hematology, Nanfang Hospital Affiliated to Nanfang Medical University, Guangzhou, China

    X
  • Xiao-Qin Chen,

    Affiliation: Department of Hematology, the Cancer Hospital, Sun Yat-Sen University, Guangzhou, China

    X
  • Jing-Lei Liu,

    Affiliations: Laboratory of Molecular Target-Based Therapy for Cancer, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China, University of Science and Technology of China, Hefei, China

    X
  • Ping Liu,

    Affiliation: State Key Laboratory of Medical Genomics and Shanghai Institute of Hematology, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

    X
  • Zhu Chen,

    Affiliation: State Key Laboratory of Medical Genomics and Shanghai Institute of Hematology, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

    X
  • Sai-Juan Chen mail,

    sjchen@stn.sh.cn (SJC); gbzhou@ioz.ac.cn (GBZ)

    Affiliation: State Key Laboratory of Medical Genomics and Shanghai Institute of Hematology, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

    X
  • Guang-Biao Zhou mail

    sjchen@stn.sh.cn (SJC); gbzhou@ioz.ac.cn (GBZ)

    Affiliations: Laboratory of Molecular Target-Based Therapy for Cancer, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China, Laboratory of Molecular Carcinogenesis and Targeted Therapy for Cancer, State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China

    X
  • Published: July 16, 2009
  • DOI: 10.1371/journal.pone.0006257

About the Authors

Zheng Hu, Xiao-Fen Pan, Fu-Qun Wu, Da-Peng Liu, Ying Liu, Ting-Ting Feng, Jing-Lei Liu, Guang-Biao Zhou
Laboratory of Molecular Target-Based Therapy for Cancer, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China
Li-Yuan Ma, Ping Liu, Zhu Chen, Sai-Juan Chen
State Key Laboratory of Medical Genomics and Shanghai Institute of Hematology, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
Ying Liu, Ting-Ting Feng, Jing-Lei Liu
University of Science and Technology of China, Hefei, China
Fan-Yi Meng, Xiao-Li Liu, Qian-Li Jiang
Department of Hematology, Nanfang Hospital Affiliated to Nanfang Medical University, Guangzhou, China
Xiao-Qin Chen
Department of Hematology, the Cancer Hospital, Sun Yat-Sen University, Guangzhou, China
Guang-Biao Zhou
Laboratory of Molecular Carcinogenesis and Targeted Therapy for Cancer, State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China

Corresponding Authors

Competing Interests

The authors have declared that no competing interests exist.

Author Contributions

Conceived and designed the experiments: GZ. Performed the experiments: ZH XFP FQW LYM YL TTF XQC JLL PL. Analyzed the data: DPL XLL ZC SJC GZ. Contributed reagents/materials/analysis tools: FYM QLJ. Wrote the paper: SJC GZ.